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Hexahydro‑1,3,5‑trinitro‑1,3,5‑triazine 
(RDX, also known as hexogen or cyclonite) is 
a common environmental pollutant resulting 
from military and civil activities. According 
to the U.S. Department of Defense, an esti‑
mated 12,000 sites across the United States 
have been contaminated with explosives, 
including RDX. Concentrations of RDX 
in soils exceed thousands of milligrams per 
kilogram (Jenkins et al. 2006). RDX and 
its metabolites were also identified in water 
sources, including groundwater (Beller and 
Tiemeier 2002).
Environmental contamination by RDX 
and its N‑nitroso metabolites has raised health 
concerns about human and environmental 
exposure (Zhang et al. 2008). It has long 
been known that RDX exposure causes neu‑
rotoxicity, immunotoxicity, and an increased 
likelihood of cancers. A causal relationship 
has been established between seizures and 
acute occupational RDX exposure in humans, 
with results confirmed in laboratory animals 
(Burdette et al. 1988; Pan et al. 2007; Testud 
et al. 1996). One early study demonstrated 
that RDX exposure elevated the incidence of 
tumors in B6C3F1 mice (Lish et al. 1984). 
Based on these findings, RDX has been clas‑
sified as a class C potential human carcino‑
gen by the U.S. Environmental Protection 
Agency (U.S. EPA 1988). Despite evidence 
supporting the role of RDX as a cytotoxic 
agent and potential chemical carcinogen, 
the molecular mechanism of RDX‑induced 
neurotoxicity and potential carcinogenesis 
remains unknown.
Recently identified microRNAs (miRNAs) 
may play an important role in RDX exposure 
and in the process of RDX‑induced tum‑
origenesis and neurotoxicity. miRNAs are a 
group of small non‑protein‑coding endoge‑
nous RNAs that posttranscriptionally regulate 
the expression of > 30% of human protein‑
coding genes (Lewis et al. 2005). miRNAs 
negatively regulate gene expression through 
translation inhibition, mRNA cleavage, or 
deadenylation/decap‑mediated mRNA decay 
(Giraldez et al. 2006; Wu et al. 2006). These 
mechanisms are likely governed by the degree 
of complementarity between mRNAs and 
their targeting miRNAs (Zhang et al. 2007b). 
In animals, most miRNAs bind to their target 
mRNAs imperfectly for repressing protein 
translation at multiple complementary sites 
within the 3' untranslated regions (UTRs) 
(Ambros 2001), with a few exemptions at 
the open reading frames or 5' UTRs (Lytle 
et al. 2007). Many miRNAs are evolution‑
arily conserved in animals, from worms to 
humans (Pasquinelli et al. 2000), suggesting 
that miRNA functions are conserved from 
species to species.
miRNAs play an important role in almost 
all fundamental biological and metabolic 
processes in eukaryotic organisms (Zhang 
et al. 2007b). Many recent studies have dem‑
onstrated that miRNAs regulate cancer devel‑
opment, including cancer invasiveness and 
metastasis. Most commonly occurring cancers 
are associated with the aberrant expression 
of at least one miRNA (Zhang et al. 2007a). 
Moreover, it has been established that spe‑
cific cancers have their unique miRNA expres‑
sion profiles (Lu et al. 2005), suggesting that 
miRNAs respond to different cancers in differ‑
ent ways. Thus, miRNA profiles are useful for 
classifying and identifying cancers. Changes 
in miRNA expression can regulate the cancer 
development cascade. A recent in vitro study 
showed that transient overexpression of the 
miRNA let‑7 in A549 lung adenocarcinoma 
cell lines inhibited lung cancer cell prolifera‑
tion (Takamizawa et al. 2004). Another study 
found that changes in the expression levels of a 
single miRNA (miR‑10b) could initiate tumor 
invasion and metastasis (Ma et al. 2007).
It is well known that many chemical 
toxicants and biological toxins cause dif‑
ferent types of cancers. Although various 
environmental carcinogens cause DNA and 
chromosome damage as well as the aber‑
rant expressions of cancer‑related genes and 
toxicant‑metabolizing enzymes, the patho‑
genic mechanisms of toxicant/toxin‑induced 
cancers are unclear (de Kok et al. 2005; 
Myllynen et al. 2007). Because miRNAs play 
important roles in cancer development, and 
the aberrant expression of miRNAs has been 
observed in different cancers, we hypothesized 
that the exposure to a specific environmental 
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procarcinogen, such as RDX, would induce 
alterations in miRNA expression, and that 
the altered miRNA expression contributes 
to carcinogenesis. To test this hypothesis, we 
exposed B6C3F1 mice to RDX and inves‑
tigated the effect of RDX exposure on the 
global expression profile of miRNAs, particu‑
larly on the oncogenic, tumor‑suppressing, 
and disease‑related miRNAs. We assayed 
RDX‑induced changes in miRNAs using 
microarray and quantitative real‑time poly‑
merase chain reaction (qRT‑PCR) technolo‑
gies. Given that miRNAs are highly conserved 
between mice and humans, the results would 
help us better understand the molecular 
mechanisms of RDX‑related diseases, includ‑
ing potential carcinogenic and neurologic 
damages.
Materials and Methods
Animal treatment. We purchased female, vir‑
gin, B6C3F1 mice (Mus muscaris), at 9–11 
weeks of age, from Charles River Laboratories, 
Inc. (Wilmington, MA). Mice were accli‑
mated to the laboratory environment for 
5 days before administering dietary RDX. 
Twenty‑one mice were randomly assigned 
to treatment or control groups. Each cage 
housed three mice, and all cages were located 
in an animal room with temperature rang‑
ing from 68°F to 72°F and 25–75% rela‑
tive humidity with 16/8‑hr light/dark cycle. 
RDX‑spiked food was used to feed mice and 
tap water was provided ad libitum, and their 
behavior and the weight of food and drinking 
water were carefully monitored twice per day. 
Animal use and handling protocols complied 
with Texas Tech University Animal Use and 
Care Committee guidelines. We treated all 
mice humanely and with regard for alleviation 
of suffering.
The mice in treatment groups were fed 
using finely ground Purina Certified Rodent 
Chow No. 5002 (Purina Mills, St. Louis, 
MO) containing 5 mg/kg RDX. RDX was 
dissolved in acetone and then sprayed onto 
the rodent chow to produce a dosage of 5 
mg/kg. For the control group, we sprayed the 
same amount of acetone used in the RDX 
food preparation onto the rodent chow as a 
vehicle control. We thoroughly mixed the 
RDX‑treated mouse food for at least 30 min 
after spraying with the acetone‑solubilized 
solution and then spread it in a well‑venti‑
lated area to allow the acetone to evaporate 
for 4 days before use. The actual amount of 
RDX in the rodent chow was measured using 
pressurized liquid extraction followed by gas 
chromatography with electron‑capture detec‑
tion (Pan et al. 2005).
Mouse euthanasia and organ collection. 
After 28 days of exposure, we euthanized 
both the RDX‑fed and control mice by CO2 
asphyxiation. The brain and liver tissues were 
immediately removed, weighed, and trans‑
ferred into a 2‑mL microcentrifuge tube and 
stored in liquid nitrogen during necropsy. We 
then transferred the frozen tissue samples into 
a –80°C freezer until miRNA analysis.
RNA isolation. We extracted total RNA 
from each sample (brain and liver) using the 
mirVana miRNA Isolation Kit (Ambion, 
Austin, TX) according to the manufacturer’s 
instructions. Briefly, 0.03–0.05 g tissues were 
weighed and placed in a new 2‑mL micro‑
centrifuge tube, followed by adding 300 µL 
lysis/binding buffer. Then, the tissues were 
thoroughly disrupted and homogenized using 
a Sonic Dismembrator (model 100, Fisher 
Scientific, Atlanta, GA). After homogeniza‑
tion, we added 30 µL miRNA homogenate 
additive to each tissue lysate, vortexed it for 
10 sec, and then incubated it on ice for 10 
min. After washing, we eluted the total RNAs 
using 100 µL elution buffer provided in the 
miRNA isolation kit. We performed all these 
operations on ice. The extracted RNA was 
quantified using a NanoDrop ND‑100 spec‑
trophotometer (NanoDrop Technologies, 
Wilmington, DE), aliquoted, and immedi‑
ately stored at –80°C until analysis.
miRNA microarray. The miRNA micro‑
array analysis was performed by LC Sciences 
(Houston, TX). Briefly, the assay started 
with approximately 6 µg total RNA. After 
the total RNAs were fractionated by size 
using a YM‑100 Microcon centrifugal filter 
(Millipore, Billerica, MA), poly(A) tails were 
added to RNA sequences with lengths less 
than 300 nucleotides using poly(A) poly‑
merase. Then, an oligonucleotide tag was 
ligated to the poly(A) tail for later fluorescent 
dye staining. RNA samples from liver and 
brain extracts were hybridized overnight using 
two different tags on a µParaflo microfluidic 
chip using a microcirculation pump devel‑
oped by Atactic Technologies (Houston, TX) 
(Gao et al. 2004). One of the major advan‑
tages of the µParaflo microfluidic technology 
is that it allows efficient parallel synthesis of 
a large number of different oligonucleotide 
molecules (Sun et al. 2008). Each micro‑
fluidic chip contained the following probes: 
a) detection probes, which consisted of all 
chemically modified nucleotide sequences 
complementary to all 567 mouse miRNAs 
listed in the Sanger miRNA miRBase database 
(Release 10.1: December 2007; http://www.
microrna.sanger.ac.uk/sequences/); b) a total 
of 49 positive and negative control probes 
designed by LC Sciences to ensure uniformity 
of sample labeling and assay conditions; and 
c) a spacer segment of polyethylene glycol to 
extend the coding segment away from the 
substrate. LC Sciences made the probes in situ 
using the photogenerated reagent chemistry. 
The melting temperatures of hybridization 
were balanced by chemical modifications of 
the probes, and hybridization reactions were 
performed in 100 µL 6× SSPE buffer (0.90 
M NaCl, 60 mM Na2HPO4, 6 mM EDTA, 
pH 6.8) containing 25% formamide at 34°C. 
After RNA hybridization, tag‑conjugating Cy3 
and Cy5 dyes were circulated to control and 
treatment samples, respectively, for dye stain‑
ing. Each analyzed miRNA was repeated six 
times and the controls were repeated for 4–16 
times. A GenePix 4000B (Molecular Devices, 
Union City, CA) laser scanner was used to col‑
lect the fluorescence images, which were digi‑
tized using Array‑Pro image analysis software 
(Media Cybernetics, Bethesda, MD).
miRNA microarray data analysis. We 
analyzed miRNA microarray data by subtract‑
ing the background and then normalizing 
the signals using a LOWESS filter (locally 
weighted regression), as described in a previ‑
ous report (Bolstad et al. 2003). We listed 
a miRNA as a detectable miRNA when it 
met at least three criteria: a) signal intensity 
greater than three times background stan‑
dard deviation; b) spot coefficient of variance 
(CV) < 0.5, in which we calculated CV as 
(standard deviation)/(signal intensity); and 
c) at least three of the six repeats have signal 
greater than three times background standard 
deviation. The ratio of the two sets (control 
and treatment) of detected signals (log2 trans‑
formed, balanced) and p‑values of the t‑test 
were calculated. Differentially detected signals 
were those with p‑values less than 0.01.
The detailed method for microarray 
data analysis and normalization is described 
in the Supplemental Material (http://www. 
ehponline.org/members/2008/11841/suppl.
pdf (Bolstad et al. 2003).
RT-PCR and qRT-PCR. We selected 
miRNAs with aberrant expression in micro‑
array analysis and then validated them using 
qRT‑PCR on an ABI7300 system (Applied 
Biosystems, Foster City, CA). We used 
TaqMan miRNA assays to detect and quan‑
tify mouse miRNAs using stem‑loop RT‑PCR 
according to the manufacturer’s instructions. 
We provide a detailed description of the 
method in the Supplemental Material (http://
www.ehponline.org/members/2008/11841/
suppl.pdf).
Prediction of miRNA targets. We used two 
different computational programs, TargetScan 
(Lewis et al. 2003) and PicTar (Krek et al. 
2005), to predict miRNA targets. Each pre‑
dicted gene was assigned a score from 1 to n 
according to the gene’s original score gener‑
ated by each computational program. Then, 
the two scores from both programs were 
added up to give a total score for each pre‑
dicted gene. The lower the total score a pre‑
dicted gene has, the more likely it is the real 
target gene of a specific miRNA. We identi‑
fied the 50 most promising candidate genes 
based on the additive scores. For details, see the RDX induces aberrant microRNA expression in mice
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Supplemental Material (http://www.  ehponline.
org/  members/2008/11841/suppl.pdf).
Results
miRNA expression in mouse brain and liver 
tissues. We observed differentially expressed 
patterns of miRNAs in mouse brain and liver. 
In this study, 369 miRNAs were detected 
in mouse brain and/or liver out of the 567 
currently known mouse miRNAs (Figure 1). 
Of the 369 detected miRNAs, 284 were 
detected in the liver and 326 in the brain. 
Among detected miRNAs, 20 miRNAs were 
highly expressed in the liver, and 53 miRNAs 
were highly expressed in the brain [see 
Supplemental Material, Tables 1–3 (http://
www.ehponline.org/members/2008/11841/
suppl.pdf)]. Fifteen miRNAs were highly 
expressed in both liver and brain: miR‑709, 
let‑7a, let‑7f, let‑7c, let‑7d, miR‑26a, let‑7b, 
let‑7g, miR‑26b, miR‑29a, miR‑126‑3p, 
miR‑23b, miR‑30c, miR‑16, and miR‑23a.
The expression levels were low for most of 
the detected miRNAs. Of the 369 detected 
miRNAs, 269 gave signals lower than 500 
(Figures 1 and 2). However, 89 miRNAs 
were expressed with signals greater than 
1,000; some of them with signals greater 
than 40,000. This suggests that the expression 
levels of miRNAs in mice vary greatly, with 
some produced at only a few copies per cell 
and others present in hundreds of copies. This 
observation is similar to that of a previous 
report (Lagos‑Quintana et al. 2002).
miRNA expression patterns signifi‑
cantly differ between mouse liver and brain. 
Some miRNAs were highly expressed in the 
brain but not in the liver, and vice versa [see 
Supplemental Material, Tables 1–3 (http://
www.ehponline.org/members/2008/11841/
suppl.pdf)]. In this study, 85 miRNAs were 
expressed in the brain only. Some of these 
miRNAs, for example, miR‑9, miR‑9*, 
miR‑218, miR‑204, and miR‑129‑3p, 
are highly expressed in the brain with sig‑
nals higher than 40,000. However, we did 
not detect these miRNAs in the liver, sug‑
gesting that these miRNAs are specific to 
brain relative to liver. Except for the brain‑
  specific miRNAs, the expression levels of 68 
miRNAs in the brain were at least 10‑fold 
higher than those in the liver. On the con‑
trary, 43 miRNAs were expressed in the liver 
but not in the brain, suggesting that these 
miRNAs are liver specific compared with 
brain. In addition to the 43 liver‑specific 
miRNAs, five miRNAs (miR‑148a, miR‑192, 
miR‑194, miR‑122, and miR‑21) were highly 
expressed in the liver but at low levels in the 
brain; four of them (miR‑148a, miR‑192, 
miR‑194, miR‑122) were expressed at levels 
at least 10‑fold greater in the liver than in the 
brain. miR‑10a and the miR‑689 were also 
expressed in the liver at levels 10‑fold higher 
than those in the brain[see Supplemental 
Material, Table 2 (http://www.ehponline.org/
members/2008/11841/suppl.pdf)].
RDX exposure altered miRNA expression 
profiles. A comparison of miRNA expression 
levels between control and RDX‑treated mice 
revealed that RDX exposure significantly 
altered miRNA expression profiles [Figure 3; 
see Supplemental Material, Table 1–3 (http://
www.ehponline.org/members/2008/11841/
suppl.pdf)]. RDX exposure resulted in the 
expression of a greater number of miRNAs 
in brain tissues from RDX‑treated mice com‑
pared with controls. By comparison, the total 
number of miRNAs expressed in liver tis‑
sues from RDX‑treated mice was lower than 
that in controls [see Supplemental Material, 
Table 1 (http://www.ehponline.org/mem‑
bers/2008/11841/suppl.pdf)]. In brain tissues, 
we detected 58 miRNAs in treated mice but 
not in controls, whereas we detected only four 
miRNAs (miR‑10a, miR‑10b, miR‑712*, 
and miR‑715) in control brain tissues but 
not in treated samples [see Supplemental 
Material, Table 3 (http://www.ehponline.org/ 
members/2008/11841/suppl.pdf)]. Although 
many miRNAs were aberrantly expressed 
after RDX exposure, almost all detected 
miRNAs, either in control or in treated mice 
but not in both, gave low microarray signals, 
suggesting these miRNAs were expressed 
at low levels. Interestingly, of the total 191 
miRNAs detected in one sample (either con‑
trol or treatment) but not in both, one‑third 
were miRNA* sequences. Usually, miRNA* 
sequences were quickly degraded during the 
final stage of miRNA biogenesis (Schwarz 
et al. 2003). What caused these miRNA* 
sequences to become detectable after exposure 
to RDX is unclear.
RDX exposure affected not only the total 
number of detectable miRNAs in mouse 
brain and liver, but also the expression   levels 
of miRNAs (p < 0.01; Figure 3, Tables 1 
and 2). The expression levels of 84 miRNAs 
were significantly altered in mouse brain 
Figure 1. miRNA microarray signal distribution between control samples and RDX-exposed samples in 
mouse brain tissues (A) and liver tissues (B).
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after RDX exposure (Table 1, Figures 3, 4A). 
Of the 84 miRNAs, 38 were up‑regulated 
and 46 were down‑regulated. However, the 
extent of changes varied among miRNAs. 
For example, the expression levels of miR‑
206 and miR‑497 were increased significantly 
by 26‑ and 9‑fold, respectively, whereas the 
expression of miR‑10b was decreased signifi‑
cantly by 14‑fold (Table 1). Similarly, the 
changes in miRNA expression of liver tis‑
sues varied among miRNAs (Table 2, Figures 
3, 4B). RDX exposure significantly affected 
the expression of 56 miRNAs in mouse 
liver (Table 2, Figures 3, 4B). Of these 56 
miRNAs, 31 were up‑regulated and 15 were 
down‑regulated. The most up‑regulated 
miRNAs were miR‑689, miR‑802, miR‑29c, 
and miR‑30e, and their expression levels 
were increased at least 3‑fold. In contrast, 
the expressions of some miRNAs were sig‑
nificantly inhibited by RDX exposure; the 
miRNAs with at least 4‑fold inhibition were 
miR‑574‑5p, miR‑466f‑3p, and let‑7e.
Two major evidences suggest that brain 
was more sensitive to RDX exposure than 
liver. First, the number of miRNAs exhibiting 
expression alterations after RDX exposure 
is larger in brain tissues than in liver tissues. 
Eighty‑four miRNAs have significant expres‑
sion alterations in mouse brain, whereas only 
56 miRNAs have significant expression alter‑
ations in the liver. Second, the changes in 
miRNA expression level were much higher 
and wider in the brain than in the liver. The 
fold change miRNA expression ranged from 
14‑fold down (miR‑10b) to 26.5‑fold up 
(miR‑206) in the brain, compared with only 
10‑fold down (miR‑574‑5p) to 6.5‑fold up 
(miR‑689) in the liver (Tables 1 and 2).
Of the 113 miRNAs with significantly 
aberrant expressions after RDX exposure, 
the expression levels of 10 miRNAs were 
significantly increased in both mouse liver 
and brain (p < 0.01): miR‑99a, miR‑30a, 
miR‑30d, miR‑30e, miR‑22, miR‑194, miR‑
195, miR‑15a, miR‑139‑5p, and miR‑101b. 
Three miRNAs (miR‑762, miR‑423‑5p, and 
miR‑185) had expression levels significantly 
decreased in both brain and liver (p < 0.01). 
For most miRNAs, their responses to RDX 
exposure were not consistent between brain 
and liver (Table 3). Seven miRNAs (let‑7e, 
miR‑98, miR‑361, miR‑26b, miR‑125a‑5p, 
let‑7i, and let‑7f) were significantly up‑reg‑
ulated in the brain but down‑regulated in 
the liver after RDX exposure. In contrast, 
another seven miRNAs (miR‑126‑3p, miR‑
23b, miR‑27a, miR‑29a, miR‑29c, miR‑451, 
and miR‑690) were significantly up‑regu‑
lated in the liver but down‑regulated in the 
brain. Although 37 miRNAs had significant 
expression changes in both brain and liver, 57 
miRNAs had significant expression changes in 
the brain but not in the liver and 29 miRNAs 
had significant expression changes in the liver 
but not in the brain (Table 3).
Confirmatory studies on differentially 
expressed miRNAs by qRT-PCR. To validate 
the microarray data, we assayed expression 
levels of four miRNAs (miR‑206, miR‑200c, 
miR‑27a, and let‑7e) by qRT‑PCR and com‑
pared the results from the microarray and 
qRT‑PCR. Of the miRNAs selected for com‑
parison, two miRNAs (miR‑206 and let‑7e) 
were up‑regulated whereas two miRNAs 
(miR‑200c and miR‑27a) were down‑reg‑
ulated based on the results of microarray 
analysis. The expression data obtained by 
qRT‑PCR analysis are comparable with the 
microarray analysis data (Figure 5).
Prediction of the target genes of miR-206. 
miRNAs function by targeting mRNAs for 
mRNA cleavage or translation repression. 
Thus, miRNA function studies depend heav‑
ily on the identification of miRNA targets. 
Currently, the major strategy to identify 
miRNA targets is based on various computa‑
tional programs (Zhang et al. 2006). Almost 
all currently available computational pro‑
grams overpredict miRNA targets. Several 
Figure 3. Hierarchical clustering of the differentially expressed miRNAs in control and RDX-treated 
mouse brain (A) and liver (B) samples after exposure to 5 mg/kg RDX for 28 days. Each row represents 
one miRNA with significantly differential expressions between control and treatment (p < 0.01). Each col-
umn represents a biological replicates; in each panel, the left six columns are for controls and the right 
six for RDX treatments. Colors represent expression levels of each individual miRNA: red, up-regulation; 
green, down-regulation.
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hundreds of genes have been predicted to be 
the targets of one single miRNA; only a few 
of them have been validated by experimen‑
tal approaches, and most of these predicted 
targets are likely to be false targets (Zhang 
et al. 2006). One good approach to circum‑
vent this problem is to employ two different 
computational programs to predict miRNA 
targets independently and then compare the 
two lists of targeted genes predicted by each 
program. The genes predicted by both pro‑
grams are more likely to be the real targets of 
the miRNA.
In both microarray and qRT‑PCR analy‑
ses, miR‑206 was significantly up‑regulated 
in mouse brain after exposure to RDX. The 
change of miR‑206 expression was higher 
than all other miRNAs detected in this 
study. This suggests that miR‑206 may play 
an important function in animal response to 
RDX exposure. To explore the potential func‑
tions of miR‑206, we employed two compu‑
tational programs (TargetScan and PicTar) 
to predict the targets of miR‑206. After sys‑
tematically analyzing two lists of miR‑206–
targeted genes predicted by TargetScan and 
PicTar, we identified the 50 most promising 
potential targeted genes [see Supplemental 
Material, Table 4 (http://www.ehponline.
org/members/2008/11841/suppl.pdf)]. These 
candidate targets include several categories. 
First, these candidate targets contained several 
transcriptional factors (e.g., the zinc finger 
protein, the cAMP‑responsive element bind‑
ing protein, and the paired box gene). It is 
well known that miRNAs target transcrip‑
tional factors for regulating animal develop‑
ment. Second, stress‑associated genes were 
predicted as targets of miR‑206. Third, miR‑
206 may target brain‑derived neurotrophic 
factors (BDNFs), which may cause neurologic 
disorders. Fourth, miR‑206 may directly tar‑
get cancer‑related genes, for example, met 
proto‑oncogene (NM_000245, GenBank) 
and v‑ets erythroblastosis virus E26 oncogene 
homolog 1 (NM_005238, GenBank). This 
suggests that miR‑206 may regulate multiple 
biological and metabolic processes in response 
to RDX exposure. Further investigating the 
functions of miR‑206 on these potential tar‑
geted genes will help us better understand the 
mechanism of RDX‑induced neurotoxicity 
and potential carcinogenesis.
Discussion
miRNA response to chemical exposure. We 
found the expressions of 113 miRNAs, 
belonging to 75 families, to be affected by 
RDX exposure in mice. Although a number 
of the RDX‑responsive miRNAs (let‑7, miR‑
34, miR‑146, and miR‑222) found in this 
study have been reported previously to have 
aberrant expressions in response to different 
chemical exposures in human cell lines, most 
of the RDX‑responsive miRNAs reported in 
this study have not been shown to respond to 
chemical treatment previously (Blower et al. 
2008; Marsit et al. 2006; Moffat et al. 2007; 
Pogribny et al. 2007; Rossi et al. 2007; Saito 
miRNAs  Control (Ck) signal  Treatment (T) signal  Ln (T/Ck)  Fold change
Up-regulated (n = 38)       
  miR-206  62.19  1603.19  4.73  26.53
  miR-497  78.32  683.40  3.18  9.04
  miR-195  5420.90  18586.65  1.85  3.60
  miR-101a  414.29  1384.95  1.82  3.52
  miR-194  197.96  672.73  1.80  3.49
  miR-101b  145.54  378.38  1.43  2.70
  miR-30a*  301.75  823.11  1.40  2.64
  miR-129-5p  218.09  576.45  1.39  2.63
  miR-598  392.37  957.26  1.22  2.34
  miR-122  741.33  1683.98  1.20  2.30
  miR-98  1676.79  3775.53  1.19  2.28
  miR-30e*  250.04  540.47  1.16  2.23
  miR-7a*  219.35  429.92  1.03  2.04
  miR-187  349.58  687.98  0.89  1.85
  miR-146b  362.94  611.32  0.82  1.77
  miR-28  276.74  463.37  0.80  1.74
  miR-411  287.46  486.04  0.71  1.64
  miR-16  15325.33  23835.23  0.65  1.57
  miR-30d  6457.60  10059.60  0.64  1.56
  miR-26b  8889.40  13087.02  0.61  1.52
  miR-30e  2673.12  4166.48  0.60  1.52
  miR-15a  1416.54  2199.71  0.57  1.48
  miR-22  986.42  1449.72  0.53  1.45
  miR-124  24353.80  34061.86  0.53  1.44
  miR-204  6615.88  9502.37  0.52  1.44
  miR-99a  2198.46  3034.79  0.51  1.43
  miR-129-3p  5616.21  7610.62  0.43  1.35
  miR-30a  8398.62  11447.01  0.42  1.34
  miR-139-5p  8644.69  11096.41  0.40  1.32
  let-7i  19829.87  24407.14  0.38  1.30
  miR-361  5810.54  7223.99  0.34  1.26
  miR-99b  3474.25  4415.96  0.33  1.26
  miR-181a  8172.97  9590.44  0.24  1.18
  miR-29b  6102.84  7130.04  0.23  1.17
  let-7g  28189.65  32541.92  0.21  1.15
  let-7e  24340.51  27969.73  0.18  1.13
  miR-125a-5p  30571.05  33774.05  0.14  1.10
  let-7f  35296.63  39682.61  0.14  1.10
Down-regulated (n = 46)       
  miR-9*  24490.19  21896.30  –0.16  0.89
  miR-23b  20805.98  18196.75  –0.20  0.87
  miR-23a  17809.02  15248.49  –0.22  0.86
miRNAs  Control (Ck) signal  Treatment (T) signal  Ln (T/Ck)  Fold change
  miR-29c  18243.37  15988.93  –0.22  0.86
  miR-218  19242.65  16257.02  –0.22  0.86
  miR-222  7927.73  6898.47  –0.22  0.86
  miR-191  12497.48  10563.47  –0.24  0.85
  miR-137  7815.85  6503.00  –0.25  0.84
  miR-29a  35778.41  30011.86  –0.25  0.84
  miR-126-3p  14784.18  12600.23  –0.27  0.83
  miR-183  11607.92  9357.58  –0.27  0.83
  miR-128  44764.78  36552.18  –0.31  0.81
  miR-125b-5p  43002.58  33354.35  –0.35  0.78
  miR-27a  4920.33  3500.16  –0.36  0.78
  miR-335-5p  5043.28  3912.21  –0.40  0.76
  miR-429  12415.46  9289.49  –0.42  0.75
  miR-200b  19737.09  14444.82  –0.44  0.74
  miR-200a  9521.66  6901.67  –0.45  0.73
  miR-690  5227.26  3879.89  –0.45  0.73
  miR-34a  1717.74  1251.73  –0.45  0.73
  miR-185  4515.15  3236.95  –0.46  0.72
  miR-200c  10497.13  7489.56  –0.47  0.72
  miR-383  1408.73  991.23  –0.50  0.71
  miR-674  1832.33  1267.67  –0.54  0.69
  miR-376b  1191.48  807.15  –0.55  0.69
  miR-433  4293.85  2893.60  –0.55  0.68
  miR-328  2162.73  1441.62  –0.61  0.66
  miR-744  1334.35  888.29  –0.62  0.65
  miR-182  9376.05  6027.11  –0.63  0.65
  miR-330*  820.65  497.40  –0.64  0.64
  miR-181d  970.01  600.68  –0.65  0.64
  miR-181b  2470.77  1563.50  –0.67  0.63
  miR-451  2271.21  1403.72  –0.71  0.61
  miR-705  1915.43  1168.91  –0.74  0.60
  miR-762  1214.54  727.44  –0.76  0.59
  miR-7a  6007.06  3500.84  –0.78  0.58
  miR-423-5p  1247.31  741.65  –0.80  0.57
  miR-1224  1215.84  660.03  –0.84  0.56
  miR-667  2752.98  1448.71  –0.88  0.54
  miR-134  439.35  224.72  –0.91  0.53
  miR-770-3p  566.45  307.74  –0.98  0.51
  miR-709  65443.45  30144.97  –1.10  0.47
  miR-199a-3p  306.18  144.31  –1.17  0.44
  miR-214  258.41  108.21  –1.21  0.43
  miR-1  462.98  194.98  –1.22  0.43
  miR-10b  137.98  10.11  –3.80  0.07
Table 1. Eighty-four miRNAs with significant expression levels in mouse brain tissues after exposure to 5 mg/kg RDX for 28 days (p < 0.01). Zhang and Pan
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et al. 2006; Sun et al. 2008). These results 
suggest that either the spectrum of miRNAs 
that respond to chemical treatment is unique 
for specific groups of chemicals or that there 
are methodologic differences in detection of 
chemically responsive miRNAs. The investi‑
gation of the effect of different chemicals on 
miRNA expression profiles will allow a bet‑
ter understanding of the response spectrum 
of miRNAs in relation to chemical‑induced 
toxicity and diseases. A particularly interesting 
potential application of these results is the use 
of miRNA response profile to develop a set 
of sensitive biomarkers for monitoring and 
assessing the health effects of environmental 
toxicants.
The research reported here possibly marks 
the first time that the effects of an environ‑
mental toxicant on the expression of miRNAs 
has been examined in vivo. Consequently, 
we are now in a position to compare these 
results with similar studies that have measured 
the response of miRNAs to pharmaceutical 
agents, which allows us to determine whether 
there are common miRNA response pathways 
for xenobiotic agents or whether the collec‑
tive miRNA response is a function of specific 
chemical exposure. We will also be able to use 
the results of this research to understand the 
effects of environmental toxicants on environ‑
mental and human health.
This is also the first comparison study of 
miRNA expression in different tissues of mice 
exposed to an environmental toxicant. The 
contrasting expression of a same miRNA in 
brain relative to liver (some miRNAs were 
up‑regulated in brain but down‑regulated in 
liver and vice versa) indicates that there is tis‑
sue‑specific variation in response to the same 
chemical and that miRNAs may play differ‑
ent roles in different tissues. We also deter‑
mined that the response of brain miRNAs to 
RDX exposure was more pronounced than 
that of the liver, which is indicative that the 
toxic effects of RDX exposure may be more 
severe in the brain than in the liver (Figure 4). 
This further suggests that miRNAs respond to 
chemical exposure in a tissue‑specific manner 
and that the toxicity may be mediated, at least 
in part, through miRNAs.
RDX-induced regulation of miRNAs 
and their targets involved in neurotoxic-
ity. It has been well known for some time 
that RDX exposure causes adverse central 
nervous system (CNS) syndromes, includ‑
ing convulsion, epileptic seizure, and loss 
of reflexes in human and experimental ani‑
mals (Burdette et al. 1988; Goldberg et al. 
1992; Levine et al. 1981; Pan et al. 2007; 
Testud et al. 1996). However, the molecular 
mechanism of RDX‑induced neurotoxicity 
is unknown. In this study, we documented 
significant changes in miRNA expression in 
the brains of RDX‑treated animals relative to 
their untreated controls. Of particular inter‑
est, miR‑206 exhibited the most significant 
up‑regulation (26‑fold) in RDX‑exposed 
mouse brain relative to controls. This result 
is notable because the BDNF gene is among 
the potential miR‑206 targets. BDNF is one 
of the most important members of the neu‑
rotrophin family, and it is broadly expressed 
in mammalian (including human) CNS and 
peripheral nervous system and is thought to 
play important roles in supporting neuronal 
survival and differentiation, neurite out‑
growth, and synaptic plasticity (Murer et al. 
2001). Neurodegenerative diseases, including 
Alzheimer’s disease and Parkinson disease, 
have been associated with reduced BDNF 
expression (Murer et al. 2001). One recent 
study demonstrated that the environmen‑
tal toxicant polybrominated diphenyl ethers 
reduced BDNF proteins in hippocampus of 
Table 2. Fifty-six miRNAs with significant expression levels in mouse liver tissues after exposure to 
5 mg/kg RDX for 28 days (p < 0.01). 
miRNAs  Control (Ck) Signal  Treatment (T) Signal  Ln (T/Ck)  Fold change
Up-regulated (n = 31)       
  miR-689  53.64  321.49  2.69  6.47
  miR-802  102.06  452.31  2.25  4.76
  miR-29c  650.72  2353.21  1.87  3.66
  miR-30e  241.16  872.41  1.85  3.62
  miR-148a  2798.83  8285.51  1.53  2.88
  miR-192  8975.90  23801.68  1.49  2.82
  miR-99a  62.76  182.85  1.48  2.79
  miR-101b  271.45  691.85  1.32  2.49
  miR-152  138.25  411.63  1.31  2.48
  miR-29a  5693.53  13089.25  1.24  2.36
  miR-30a  1231.17  2988.00  1.23  2.34
  miR-93  85.17  186.80  1.10  2.14
  miR-15a  493.75  978.07  1.04  2.06
  miR-139-5p  129.23  295.12  1.03  2.05
  miR-194  6147.52  12165.48  1.00  1.99
  miR-27a  806.70  1598.30  0.99  1.98
  miR-690  827.18  1477.09  0.86  1.82
  miR-20a  344.54  589.10  0.80  1.75
  miR-195  375.51  619.41  0.79  1.73
  miR-22  900.37  1538.86  0.79  1.73
  miR-451  885.93  1482.35  0.74  1.67
  miR-30d  1156.83  1791.33  0.60  1.51
  miR-126-3p  7922.97  11017.61  0.54  1.45
  miR-25  557.96  796.59  0.51  1.42
  miR-24  1582.59  2283.18  0.50  1.41
  miR-27b  2272.75  3102.84  0.48  1.39
  miR-143  667.41  1005.61  0.48  1.39
  miR-23b  7607.74  9496.82  0.35  1.27
  miR-26a  19218.42  23515.59  0.34  1.27
  miR-23a  5561.59  6882.01  0.30  1.23
  miR-30c  6790.49  8329.45  0.29  1.22
Down-regulated (n = 25)       
  miR-26b  12561.71  9299.89  –0.38  0.77
  let-7i  3777.32  2842.92  –0.42  0.75
  miR-125a-5p  1505.59  1067.46  –0.47  0.72
  miR-92a  3658.17  2635.02  –0.47  0.72
  let-7a  31984.07  20972.51  –0.54  0.69
  let-7c  29197.98  18108.06  –0.60  0.66
  miR-151-5p  1583.62  967.48  –0.61  0.66
  let-7d  27906.40  17206.77  –0.62  0.65
  let-7f  31965.56  20730.37  –0.63  0.65
  miR-361  1316.31  813.85  –0.66  0.63
  miR-185  766.30  489.99  –0.67  0.63
  miR-15b  1419.61  831.88  –0.75  0.60
  miR-107  1044.56  607.84  –0.80  0.57
  let-7b  24395.46  13082.76  –0.80  0.57
  miR-103  1112.64  590.07  –0.83  0.56
  miR-145  861.14  456.09  –0.88  0.54
  miR-423-5p  640.50  338.97  –0.91  0.53
  miR-320  1031.88  524.74  –0.95  0.52
  miR-762  2142.91  1069.24  –0.98  0.51
  miR-486  866.92  347.48  –1.27  0.42
  miR-98  304.26  119.05  –1.32  0.40
  miR-805  3046.89  1115.89  –1.42  0.37
  let-7e  6778.31  1657.50  –2.01  0.25
  miR-466f-3p  241.33  55.51  –2.17  0.22
  miR-574-5p  1012.75  94.86  –3.37  0.10RDX induces aberrant microRNA expression in mice
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mice (Viberg et al. 2008), which suggests that 
neurotoxic environmental toxicants may exert 
their toxic effects through their activity on 
BDNF expression. In this present study, six 
transcript variants of BDNF genes are uni‑
formly predicted to be the targets of miR‑206 
by both PicTar and TargetScan programs [see 
Supplemental Material, Table 4 (http://www.
ehponline.org/  members/2008/11841/suppl.
pdf)] underscoring the likelihood that RDX‑
induced increases in expression of miR‑206 
may contribute to the neurotoxicity of RDX 
in the brain through its reduction of BDNF 
gene expression.
Although the regulation of the BDNF 
gene by various factors has been extensively 
investigated at the mRNA and protein lev‑
els (Murer et al. 2001), the role of miRNAs 
in BDNF gene regulation was only recently 
reported in a study that demonstrated that 
multiple differentially expressed miRNAs act 
as inhibitors of BDNF in human prefrontal 
cortex (Mellios et al. 2008). In that study, 
luciferase assays confirmed that BDNF was 
targeted by two miRNAs, miR‑30a‑5p and 
miR‑195 (Mellios et al. 2008). Interestingly, 
Figure 4. Fold changes of miRNAs whose expression levels were significantly altered in brain tissues (A) and liver tissues (B) of mice exposed to 5 mg/kg RDX for 28 days.
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Table 3. Comparison of miRNA expression profiles between mouse liver tissues and brain tissues after 
exposure to 5 mg/kg RDX for 28 days (p < 0.01).
  miRNAs
miRNA category  No.  Name
Up-regulated in both brain and liver  10  miR-99a, miR-30e, miR-30d, miR-30a, miR-22, 
    miR-195, miR-194, miR-15a, miR-139-5p, miR-101b
Down-regulated in both brain and liver  3  miR-762, miR-423-5p, miR-185
Up-regulated in brain but down-regulated in liver  7  let-7e, miR-98, miR-361, miR-26b, miR-125a-5p, 
    let-7i, let-7f
Up-regulated in liver but down-regulated in brain  7  miR-126-3p, miR-23b, miR-27a, miR-29a, miR-29c, 
    miR-451, miR-690
Significant expression changes in brain but not in liver  57  miR-99b, miR-1, miR-101a, miR-10b, miR-122, 
    miR-1224, miR-124, miR-125b-5p, miR-128, 
    miR-129-3p, miR-129-5p, miR-134, miR-137, 
    miR-146b, miR-16, miR-181a, miR-181b, miR-181d, 
    miR-182, miR-183, miR-187, miR-191, miR-199a-3p, 
    miR-200a, miR-200b, miR-200c, miR-204, 
    miR-206, miR-214, miR-218, miR-222, miR-23a, 
    miR-28, miR-29b, miR-30a*, miR-30e*, miR-328, 
    miR-330*, miR-335-5p, miR-34a, miR-376b, 
    miR-383, miR-411, miR-429, miR-433, miR-497, 
    miR-598, miR-667, miR-674, miR-705, miR-709, 
    miR-744, miR-770-3p, miR-7a, miR-7a*, miR-9*, 
    let-7g
Significant expression changes in liver but not in brain  29  let-7a, let-7b, let-7c, let-7d, miR-103, miR-107, 
    miR-143, miR-145, miR-148a, miR-151-5p, miR-152, 
    miR-15b, miR-192, miR-20a, miR-23a, miR-24, 
    miR-25, miR-26a, miR-27b, miR-30c, miR-320, 
    miR-466f-3p, miR-486, miR-574-5p, miR-689, 
    miR-802, miR-805, miR-92a, miR-93Zhang and Pan
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we also found these two confirmed BDNF‑
targeting miRNAs (miR‑30a and miR‑195) 
were significantly up‑regulated in mouse 
brain and liver after RDX exposure (Tables 
1 and 2, Figure 4). In addition, two other 
members of the miR‑30 family (miR‑30d 
and miR‑30e) that target BDNF (Mellios 
et al. 2008) were also overexpressed (Tables 
1 and 2, Figure 4). This supports the role of 
BDNF as a potentially significant target gene 
of multiple miRNAs. Mellios et al. (2008) 
failed to detect miR‑206 expression in human 
parietal cortex tissues using microarray analy‑
sis, although they predicted computationally 
that a target site for miR‑206 exists in BDNF 
gene. However, both our microarray and 
qRT‑PCR findings indicate that miR‑206 
was strongly up‑regulated in brain tissues of 
mice exposed to RDX. These results suggests 
several alternative but not mutually exclusive 
hypotheses, including a regulatory interaction 
between miR‑206 and BDNF that responds 
significantly to RDX treatment in brain tis‑
sues, or that miR‑206 may be a stress response 
miRNA that only activates in response to spe‑
cific toxicant exposure, including RDX.
RDX-induced regulation of miRNAs and 
their targets involved in carcinogenesis. U.S. 
EPA has classified RDX as a class C potential 
human carcinogen (U.S. EPA 1988) based on 
a laboratory study in which RDX exposure 
elevated tumor incidence in B6C3F1 mice 
(Lish et al. 1984). However, the molecular 
mechanism of the RDX‑induced carcinogen‑
esis remains unknown. An interesting finding 
of this study is that a number of miRNAs 
with aberrant expressions after RDX expo‑
sure are also frequently deregulated in a wide 
range of cancers. Since the initial report link‑
ing miRNAs and cancer development (Calin 
et al. 2002), almost all types of cancers have 
been found to be associated with the aberrant 
expression of at least one miRNA, in which 
miRNAs function as oncogenes or tumor 
suppressor genes (Wiemer 2007; Zhang et al. 
2007a). Importantly, over‑ or underexpression 
of one single miRNA resulted in tumor cell 
growth inhibition (Takamizawa et al. 2004) 
or tumor invasion and metastasis (Ma et al. 
2007). For example, overexpression of miRNA 
let‑7 significantly inhibited A549 lung can‑
cer cell growth in vitro (Takamizawa et al. 
2004), suggesting a potential novel approach 
for clinical cancer gene therapy by controlling 
Figure 6. A proposed model showing the mechanisms of RDX-induced CNS disorder (A) and carcino-
genesis (B). In this model, continuous lines show steps confirmed in this study or elsewhere; the dashed 
lines represent processes that have not been proved by direct evidence. RDX exposure caused aberrant 
expressions of many miRNAs. Some of them, for example, miR-106, miR-30, and miR-195, target BDNF, one 
of the most important members in the neurotrophin family that is widely expressed in mammalian CNS 
and peripheral nervous system (Murer et al. 2001; Wetmore et al. 1991). RDX-induced overexpression of 
miRNAs (miR-206, miR-30, and miR-195) inhibits the expression of BDNF gene, which contributes to neuro-
toxicity and CNS disorders. RDX exposure also induced aberrant expressions of onco-miRNAs and tumor-
suppressing miRNAs that would directly or indirectly regulate tumor pathogenesis or target genes related 
to cell cycle (e.g., TNKS) to regulate cell apoptosis and cancer development. These proposed molecular 
changes, together with others, eventually cause RDX-induced carcinogenesis and CNS   disorders. 
However, more studies need to be performed for testing this model.
RDX exposure RDX exposure
miRNA aberrant expression
(niR-206↑, miR-30↑, mir-195↑)
BDNF ↓
CNS disorder
and
neurotoxicity
Once-miRNAs↑
tumor suppressing miRNA↓
?
TNKS
Apoptosis
miRNAs
deregulation
Carcinogenesis
A B
Table 4. Identification of currently known cancer-related miRNAs, whose expression levels were signifi-
cantly altered after exposure to 5 mg/kg RDX for 28 days (p < 0.01). 
  miRNAs with significantly altered expression 
  levels after exposure to RDX (p < 0.01) 
Brain  Liver  Cancersa
let-7↑  let-7↓  Lung cancer, prostate cancer, colorectal neoplasia
  miR-103↓  Stomach cancer
miR-10b↓    Breast cancer, colorectal neoplasia
miR-125a↑, miR-125b↓  miR-125a↓  Breast cancer, ovarian cancer, HCC
miR-128↓    Brain cancer (glioblastoma), prostate cancer
  miR-143↑  Colorectal neoplasia
  miR-145↓  Breast cancer, ovarian cancer, colorectal neoplasia
miR-146b↑    Breast cancer, papillary thyroid carcinoma
  miR-148a↑  Pancreatic cancer
miR-15a↑  miR-15a↑, miR-15b↓  CLL, pituitary adenomas
  miR-152↑  Pituitary adenomas
miR-16↑    CLL, pituitary adenomas
miR-181a↑, miR-181b,d↓    Brain cancer (glioblastoma), papillary thyroid carcinoma, 
      pancreatic cancer
miR-183↓    Colorectal neoplasia
miR-191↓    Pituitary adenomas
  miR-192↑  Pituitary adenomas
miR-195↑  miR-195↑  Prostate cancer, HCC
miR-199a3p↓    Ovarian cancer
miR-200a,b,c↓    HCC, ovarian cancer, cholangiocarcinoma
  miR-20a↑  Colorectal neoplasia
miR-218↓    Stomach cancer
miR-222↓    Papillary thyroid carcinoma
  miR-24↑  Pituitary adenomas
miR-26b↑  miR-26a↑, miR-26b↓  Pituitary adenomas
miR-98↑  miR-98↓  Pituitary adenomas
↑, up-regulation; ↓, down-regulation. 
aAbbreviations: CLL, chronic lymphocytic leukemia; HCC, hepatocellular carcinoma.
Figure 5. Confirmatory studies of selected miRNAs 
by TaqMan RT-PCR. The fold changes refer to the 
expression fold changes of the selected miRNAs 
in RDX-treated mice comparing with control mice. 
Values represent the mean ± SD of three indepen-
dent samples, each run in triplicate.
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the expression of a single miRNA (Zhang 
and Farwell 2008). In this study, we found 
that many cancer‑related miRNAs, such as 
let‑7, miR‑17‑92, miR‑10b, 125b, miR‑146, 
miR‑15, miR‑200, and miR‑16, were signifi‑
cantly affected by RDX exposure (Table 4). 
Expression profiles of these miRNAs were 
significantly altered in many types of can‑
cers, such as breast, lung, ovarian, liver, and 
prostate cancer, colorectal neoplasia, hepato‑
cellular carcinoma, and chronic lymphocytic 
leukemia (Zhang et al. 2007a). This suggests 
that miRNAs may be involved in RDX‑
induced carcinogenesis.
In addition to the possibility that RDX‑
induced miRNAs are involved in carcino‑
genesis, we found that several potential 
miRNA‑targeted genes are involved in cancer 
development. One example is the TNKS-2 
gene cluster (tankyrase 2, TRF1‑interacting 
ankyrin‑related ADP‑ribose polymerase 
2; NM_025235, GenBank), which is pre‑
dicted to be a potential target of miR‑206 
[see Supplemental Material, Table 4 (http://
www.ehponline.org/members/2008/11841/
suppl.pdf)]. TNKS-2 and its close homolog 
TNKS-1 are positive regulators of telomere 
elongation, which is important for the perpet‑
ual growth of cancer cells (Cook et al. 2002). 
TNKS functions by interacting with telomeric 
repeat binding factor 1 (TRF1), which inhibits 
the telomerase activity to terminate telomere 
elongation. Binding of TRF1 to the telom‑
ere can be inhibited by ADP ribosylation of 
TRF1 by TNKS-1 and TNKS-2 (Cook et al. 
2002; Smith et al. 1998). Aberrant expres‑
sion of TNKS has been found in cancers and 
neoplasms, including multiple myeloma, 
plasma cell leukemia (Xu et al. 2001), bladder 
and colon cancer (Shebzukhov et al. 2008), 
and breast cancer (Sidorova et al. 2006). 
Knockdown of TNKS-1 by small interfering 
RNA blocked mitosis due to sister chromatids 
remaining associated in telomeres (Dynek and 
Smith 2004). The inhibition of tankyrase and 
telomerase caused telomere shortening and 
apoptosis, which has been proposed as a poten‑
tial cancer therapy (Seimiya 2006). Despite 
the association among TRF-1 and TNKS and 
cell growth control, there have been no reports 
concerning miRNA‑mediated regulation 
of TNKS gene clusters. We observed, using 
combined PicTar and TargetScan analyses, 
that TNKS-2 was a target of miR‑206, which 
implies that the strong up‑regulation of miR‑
206 may target TNKS-2, which in turn may 
be a protective mechanism against the poten‑
tial carcinogenic effects of RDX by inducing 
telomere elongation termination and apop‑
tosis. This provides a new insight to elucidate 
carcinogenesis potentials of RDX.
Analyses of differentially expressed 
miRNAs and their targets in brain and liver 
tissues of mice exposed to RDX indicate that 
several miRNAs and their potential targets 
are involved in a complex regulatory net‑
work that encompasses a host of biological 
and metabolic processes. The RDX‑induced 
miRNA‑mediated changes in these processes 
have the potential to contribute to the RDX‑
induced heath effects, including neurotoxic‑
ity and potential carcinogenesis, two major 
concerns related to RDX exposure. miRNAs 
may directly and/or indirectly (through 
regulating other genes) affect the action of 
RDX on tumor pathogenesis and neurotox‑
icity (Figure 6). Recent studies on miRNA 
functions in carcinogenesis, cancer metasta‑
sis, and CNS disorders provide further sup‑
port for this hypothesis. Further investigating 
the roles of miR‑206 in regulation of BDNF 
and TNKS-2 may lead to a novel miRNA‑
related gene therapy for the treatment of dis‑
eases associated with BDNF and TNKS gene 
expression. Also, the study of stress response 
miRNAs will facilitate the development of 
sensitive miRNA biomarkers for monitoring 
the health effects of environmental toxicants.
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